NEW YORK, Dec. 27, 2017 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on TVTY, PRAH, DGX, and LH which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com revisits the Healthcare sector, which consists of companies that provide medical services, manufacture medical equipment or drugs, provide medical insurance, or otherwise facilitate the provision of healthcare to patients. Under assessment this morning are: Tivity Health Inc. (NASDAQ: TVTY), PRA Health Sciences Inc. (NASDAQ: PRAH), Quest Diagnostics Inc. (NYSE: DGX), and Laboratory Corp. of America Holdings (NYSE: LH). All you have to do is sign up today for this free limited time offer, click the link below. www.wallstequities.com/registration
Franklin, Tennessee headquartered Tivity Health Inc.'s stock finished Tuesday's session 0.14% higher at $36.50 with a total trading volume of 184,065 shares. Over the last month and since the start of this year, the Company's shares have advanced 3.99% and 60.44%, respectively. The stock is trading above its 200-day moving average by 1.13%. Moreover, shares of Tivity Health have a Relative Strength Index (RSI) of 52.32.
On December 20th, 2017, Tivity Health announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference, to be held from January 08th, 2017, to January 11th, 2018 in San Francisco. Donato Tramuto, CEO, will present on January 10th, 2018, at 11:00 a.m. EST. The presentation and presentation materials will be available under the Investors section of the Company's website. Get the full research report on TVTY for free by clicking below at: www.wallstequities.com/registration/?symbol=TVTY
PRA Health Sciences
Shares in Raleigh, North Carolina headquartered PRA Health Sciences Inc. declined 0.43%, ending yesterday's session at $91.14 with a total trading volume of 203,056 shares. The stock has gained 9.48% in the past month, 23.41% in the previous three months, and 65.35% on an YTD basis. The Company's shares are trading 9.59% above their 50-day moving average and 22.14% above their 200-day moving average. Moreover, shares of PRA Health Sciences have an RSI of 72.07.
On December 11th, 2017, research firm Barclays initiated an 'Overweight' rating on the Company's stock, with a target price of $94 per share. Find your free research report PRAH at: www.wallstequities.com/registration/?symbol=PRAH
On Tuesday, Madison, New Jersey headquartered Quest Diagnostics Inc.'s stock climbed 0.03%, to close the day at $99.27. A total volume of 365,585 shares was traded. The Company's shares have advanced 8.35% in the last one month, 5.27% in the previous three months, and 8.02% on an YTD basis. The stock is trading 4.56% above its 50-day moving average. Additionally, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have an RSI of 63.26.
On December 12th, 2017, Quest Diagnostics (DGX) announced that it has completed its previously announced acquisition of the Shiel Medical Laboratory business from Fresenius Medical Care, a premier health care company focused on renal and other chronic conditions. DGX's clinical laboratory in Teterboro, NJ will now provide services previously provided by Shiel in the New York-New Jersey metropolitan area. Patients and providers will benefit from direct access to the Company's broader test menu and from an expansive network of DGX's patient service centers in the region. Sign up today for the free research report on DGX at: www.wallstequities.com/registration/?symbol=DGX
Laboratory Corp. of America Holdings
Shares in Burlington, North Carolina headquartered Laboratory Corp. of America Holdings (LabCorp) ended the day 0.20% higher at $161.04. A total volume of 230,555 shares was traded. The stock has gained 6.59% in the last one month, 6.78% in the previous three months, and 25.44% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 4.67% and 7.51%, respectively. Furthermore, shares of LabCorp, which operates as an independent clinical laboratory company worldwide, have an RSI of 61.34.
On December 01st, 2017, research firm Mizuho reiterated its 'Neutral' rating on the Company's stock with an increase of the target price from $160 a share to $165 a share.
On December 11th, 2017, LabCorp issued a statement regarding the lawsuit filed by the American Clinical Laboratory Association against the Acting Secretary of the US Department of Health and Human Services (HHS) in the US District Court for the District of Columbia. The lawsuit alleges that the Centers for Medicare & Medicaid Services, operating under the purview of HHS, ignored the clear language of the Protecting Access to Medicare Act, and instituted a highly flawed, data reporting process that prohibited the overwhelming majority of laboratories from reporting private payer data used to determine Medicare rates for lab tests. Wall St. Equities' research coverage also includes the downloadable free report on LH at: www.wallstequities.com/registration/?symbol=LH
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities